Literature DB >> 21861992

Characterization of peripheral blood acetylcholine receptor-binding B cells in experimental myasthenia gravis.

Windy Allman1, Shamsher S Saini, Erdem Tuzun, Premkumar Christadoss.   

Abstract

In myasthenia gravis (MG), the neuromuscular transmission is impaired by antibodies (Abs) specific for muscle acetylcholine receptor (AChR). Anti-AChR Abs can be detected in the serum of MG patients, although their levels do not correlate with disease severity. In this study, we developed a flow cytometric assay for the detection of peripheral blood AChR-specific B cells to characterize B cell phenotypes associated with experimental autoimmune myasthenia gravis (EAMG). Alexa-conjugated AChR was used as a probe for AChR-specific B cells (B220+Ig+). Mice with EAMG had significantly elevated frequencies of AChR-specific IgG2+ and IgM+ B cells. While the frequencies of IgG2+ B cells and plasma anti-AChR IgG2 levels significantly correlated with the clinical grades of EAMG, the frequencies of IgM+ B cells and plasma anti-AChR IgM levels did not. These results indicate that the frequency of AChR-specific and IgG1+ (mouse IgG2 equivalent) peripheral blood B cells and anti-AChR IgG1 levels could be potential biomarkers for MG disease severity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21861992     DOI: 10.1016/j.cellimm.2011.07.007

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

1.  IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice.

Authors:  Ruksana Huda; Richard T Strait; Erdem Tüzün; Fred D Finkelman; Premkumar Christadoss
Journal:  J Neuroimmunol       Date:  2015-03-06       Impact factor: 3.478

2.  Use of Toll-Like Receptor Agonists to Induce Ectopic Lymphoid Structures in Myasthenia Gravis Mouse Models.

Authors:  Marieke Robinet; Bérengère Villeret; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Front Immunol       Date:  2017-08-25       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.